von willebrand factor concentrate during ecmo support

Conditions: Acquired Von Willebrand Disease

Summary: during treatments with extracorporeal circuits such as extracorporeal membrane oxygenation (ecmo) degradation of high molecular weight (hmw) of von willebrand factor (vwf) multimers occur leading to an acquired von willebrand disease. this disease is associated with increased bleeding and requirement for the transfusion with allogenic blood products especially packed red blood cells (prbcs). a continuous treatment with von willebrand factor concentrate (vwfc) may restore the multimers and bleeding can be avoided. therefore a randomized, double-blind, prospective, controlled, two-arm clinical trial was designed, comparing patients receiving vwfc versus placebo.

increased shear stress during mechanical circulatory support (mcs) by extracorporeal membrane oxygenation (ecmo) and ventricular assist devices (vad) can provoke premature degradation of high molecular weight (hmw) of von willebrand factor (vwf) multimers. in patients with intractable cardiac and/or respiratory failure requiring emergency ecmo support, the investigators recently demonstrated an essential decrease in high molecular weight (hmw) vwf multimer bands 24 and 48 hours after initiation of ecmo compared to baseline. blood loss and transfusion requirement during and shortly after ecmo support may be strengthened by loss of hmw vwf multimers. administration of vwf concentrates may support restoration of primary hemostasis in patients during ecmo support. consequently the need for packed red blood cells (prbcs) during ecmo support may be reduced thus positively influencing morbidity and mortality of ecmo patients. the investigators hypothesize, that treatment with vwf concentrate reduces the need for prbcs during ecmo support. therefore the primary aim of this clinical trial is to find out if the need of prbcs differs in the group receiving a von willebrand factor concentrate (vwfc), or the placebo group (saline). this clinical trial is planned as a randomized, double-blind, prospective, controlled, two-arm, two-center study. patients with intractable cardiac and/or respiratory failure requiring emergency ecmo support undergoing surgery (department of anaesthesiology and intensive care medicine) or treated at the general and surgical intensive care unit (aci), traumatologic intensive care unit (ticu), cardiologic intensive care unit (ccu) or the icu of the department of visceral, transplant and thoracic surgery at the hospital innsbruck (tirol kliniken gmbh), austria will be enrolled in the study when meeting the inclusion- and exclusion criteria. if a patient meets the inclusion criteria and is recruited for the study, the patient will be randomized either to the group receiving vwfc or placebo s. before the implementation of the ecmo the baseline investigations need to be conducted. as soon as they are completed the ecmo cannula can be inserted. the administration of the investigational medicinal product (imp) will be start within 24h after ecmo installation. directly before imp-start blood samples (visit 2) will be drawn. after 24h (visit 3), 60h (visit 4) and on day 5 (visit 5) of the start of the study medication visits will be conducted, whereas on day 5 (visit 5) no special laboratory (measurement of hmw vwf) will be analyzed. if ecmo can be terminated, a visit (visit 6) directly before the stop of the ecmo will be conducted. 36 h after the termination of the ecmo visit 7 (termination) will be performed. if the ecmo is needed longer than 7 days, the administration of the imp will be stopped on day 7 and a visit after 36 hours of imp-stop will be done for safety reasons but without special laboratory. after 30 days an interview will be performed with the treating physician.

Eligibility criteria:
inclusion criteria: * patients with the need of veno-arterial or veno-venous ecmo for a minimum of 48 hours * age ≥ 18 years exclusion criteria: * patient with known thromboembolic event in the last 30 days * inevitable lethal course * severe liver failure: quick \< 30 % * pregnancy * patient with known refusal of a participation in this clinical trial * active participation in another clinical trial * any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study or confound the ability to interpret data from the study